BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Li W, Wen W, Xie D, Qiu M, Cai X, Zheng S, Huang Y. Association between non-alcoholic fatty liver disease and risk of incident heart failure: a meta-analysis of observational studies. Ther Adv Chronic Dis 2022;13:20406223221119626. [PMID: 36052287 DOI: 10.1177/20406223221119626] [Reference Citation Analysis]
2 Makri ES, Makri E, Polyzos SA. Combination Therapies for Nonalcoholic Fatty Liver Disease. JPM 2022;12:1166. [DOI: 10.3390/jpm12071166] [Reference Citation Analysis]
3 Polyzos SA, Katsiki N. Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer. Hormones (Athens) 2022. [PMID: 35668318 DOI: 10.1007/s42000-022-00379-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Vachliotis ID, Anastasilakis AD, Goulas A, Goulis DG, Polyzos SA. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. Diabetes Obes Metab 2022. [PMID: 35589613 DOI: 10.1111/dom.14774] [Reference Citation Analysis]
5 Polyzos SA, Lambrinoudaki I, Goulis DG. Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease. Hormones (Athens) 2022. [PMID: 35532850 DOI: 10.1007/s42000-022-00369-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Curr Atheroscler Rep 2022. [PMID: 35507279 DOI: 10.1007/s11883-022-01028-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Polyzos SA, Goulis DG, Giouleme O, Germanidis GS, Goulas A. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Curr Obes Rep 2022. [PMID: 35501557 DOI: 10.1007/s13679-022-00474-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wang M, Zhou BG, Zhang Y, Ren XF, Li L, Li B, Ai YW. Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2022;9:812030. [PMID: 35345491 DOI: 10.3389/fcvm.2022.812030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Yong JN, Ng CH, Lee CW, Chan YY, Tang ASP, Teng M, Tan DJH, Lim WH, Quek J, Xiao J, Chin YH, Foo R, Chan M, Lin W, Noureddin M, Siddiqui MS, Muthiah MD, Sanyal A, Chew NWS. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. Hepatol Int 2022. [PMID: 35320497 DOI: 10.1007/s12072-022-10319-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
10 Choi JM, Park HE, Han YM, Lee J, Lee H, Chung SJ, Lim SH, Yim JY, Chung GE. Non-alcoholic/Metabolic-Associated Fatty Liver Disease and Helicobacter pylori Additively Increase the Risk of Arterial Stiffness. Front Med 2022;9:844954. [DOI: 10.3389/fmed.2022.844954] [Reference Citation Analysis]
11 Brahma M, Ghosal S, Maruthi M, Kalangi SK. Endocytosis of LXRs: Signaling in liver and disease. Progress in Molecular Biology and Translational Science 2022. [DOI: 10.1016/bs.pmbts.2022.07.008] [Reference Citation Analysis]
12 Zou ZY, Ren TY, Fan JG. Multidisciplinary participation: The key to a cure for non-alcoholic fatty liver disease. J Dig Dis 2021. [PMID: 34697893 DOI: 10.1111/1751-2980.13060] [Reference Citation Analysis]
13 Kharechkina ES, Nikiforova AB, Belosludtsev KN, Rokitskaya TI, Antonenko YN, Kruglov AG. Pioglitazone Is a Mild Carrier-Dependent Uncoupler of Oxidative Phosphorylation and a Modulator of Mitochondrial Permeability Transition. Pharmaceuticals (Basel) 2021;14:1045. [PMID: 34681269 DOI: 10.3390/ph14101045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]